`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`MYLAN PHARMACEUTICALS INC.
`Petitioner,
`
`v.
`
`BRISTOL-MYERS SQUIBB COMPANY and PFIZER INC.,
`Patent Owners.
`
`
`U.S. Patent No. 9,326,945 to Patel et al.
`
`Inter Partes Review IPR2018-00892
`
`
`
`SECOND SUPPLEMENTAL DECLARATION OF KINAM PARK, PH.D.
`
`
`
`
`
`
`
`
`
`
`
`
`MYLAN EXHIBIT 1044
`
`
`
`
`
`
`
`
`
`
`1.
`
`I, Kinam Park, Ph.D., have been retained by counsel for Petitioner
`
`Mylan Pharmaceuticals Inc. (“Mylan”) and have previously submitted an expert
`
`Declaration (Ex. 1002) (“my Original Declaration”) in support of Mylan’s Petition
`
`for inter partes review (“IPR”) of U.S. Patent No. 9,326,945 to Patel et al. (“the
`
`’945 patent”) (Paper No. 2). I understand that the Patent Trial and Appeal Board
`
`(“PTAB”) instituted trial in this IPR on October 15, 2018 (Paper No. 24).
`
`2.
`
`I further submitted a supplemental expert Declaration (“Supplemental
`
`Declaration”) in response to post-institution objections from Patent Owners
`
`challenging the authenticity and availability of certain prior art references
`
`submitted in Mylan’s Petition and discussed in my Original Declaration. I
`
`understand that my Supplemental Declaration was served on Patent Owners in
`
`conjunction with other supplemental evidence on November 9, 2018, but has not
`
`been filed with the PTAB.
`
`3.
`
`I submit this Second Supplemental Declaration in support of
`
`Petitioner’s Motion to Correct a Typographical or Clerical Mistake in the Petition
`
`Under 37 C.F.R. § 42.104(c) and/or Petitioner’s Motion to File Supplemental
`
`Information Pursuant to 37 C.F.R. § 42.123(a).
`
`I. THE CITATION TO THE RUDNIC REFERENCE CONTAINED IN
`THE PETITION AND MY ORIGINAL DECLARATION
`CONTAINED AN OBVIOUS TYPOGRAPHICAL ERROR
`4.
`
`I note that Ex. 1010 as referred in both the Petition and my
`2
`
`
`
`
`
`
`Declaration (see, e.g., Ex. 1002, header ii and ¶¶140-143) contained an
`
`inadvertent typographical error in its citation. The citation referred to Rudnic as
`
`being published in the fourth edition of the textbook Modern Pharmaceutics in
`
`2002. This is incorrect. The citation should have instead referred to the third
`
`edition of Modern Pharmaceutics published in 1996. This inadvertent
`
`typographical error resulted from Petitioner being provided with an incorrect
`
`citation by a third party which further resulted in the incorrect cover and
`
`publishing pages from the fourth edition being placed on the copy of Rudnic
`
`supplied to me as Ex. 1010 rather than the correct pages from the third edition.
`
`II. REPLACEMENT OF THE RUDNIC REFERENCE TO CORRECT
`THE TYPOGRAPHICAL ERROR DOES NOT CHANGE THE
`SUBSTANCE OF THE RUDIC REFERENCE
`5.
`
`I have been provided by counsel with the copy of Chapter 10 from the
`
`third edition of Modern Pharmaceutics obtained from Wisconsin TechSearch
`
`(“Rudnic –WTS”) and attached as Ex. 1042. I understand supplemental evidence
`
`submitted in response to Patent Owners’ post-institution objections establishes
`
`that Rudnic – WTS is an authentic copy of Rudnic from the third edition of
`
`Modern Pharmaceutics, including the correct cover page. I have reviewed Rudnic
`
`- WTS and confirm that Rudnic, submitted as Ex. 1010 to the Petition, is correctly
`
`contained therein at the page numbers referenced. In other words, although the
`
`citation to Rudnic incorrectly referred to the reference as the fourth edition rather
`
`3
`
`
`
`
`
`
`than the third edition, the page numbers cited throughout my Original Declaration
`
`correctly corresponded to cited pages of the third edition. This confirms that the
`
`error in Ex. 1010 as originally submitted was purely typographical in nature.
`
`6.
`
`I have further reviewed the fourth edition of Modern Pharmaceutics, a
`
`true and accurate copy of which was attached to my Supplemental Declaration as
`
`Ex. 1043, and note the same chapter with substantially the same disclosure, albeit
`
`at different page numbers and with different formatting, appears in that textbook
`
`as well. For example, as I stated in my Original Declaration, Rudnic teaches that
`
`“[f]or many drugs, particularly those for which absorption is limited by the rate of
`
`dissolution, attainment of therapeutic levels may depend on achieving a small
`
`particle size.” (Ex. 1002, ¶ 141). This identical sentence appears on page 335 of
`
`the third edition and on page 289 of the fourth edition (Compare Ex. 1042 with
`
`Ex. 1043). The only differences between the two sentences are insubstantial and
`
`are the uses of “whose” instead of “for which” and “upon” instead of “on.” As
`
`further stated in my Original Declaration, Rudnic “lists sodium lauryl sulfate as a
`
`lubricant (e.g., antifrictional agent) that is commonly used in tablets and other
`
`solid dosage forms” and “further notes that when tablets using sodium lauryl
`
`sulfate as a lubricant were compared with those using magnesium stearate as a
`
`lubricant, the tablets containing sodium lauryl sulfate exhibited a significantly
`
`higher rate of dissolution.” (Ex. 1002, ¶ 142). These identical teachings are
`
`4
`
`
`
`
`
`
`found on pages 354-355 of the third edition and on pages 302-303 of the fourth
`
`edition. (Compare Ex. 1042 with Ex. 1043). Accordingly, a POSA would have
`
`readily recognized the error in the citation provided for Ex. 1010 and would have
`
`understood that the disclosure of Ex. 1010 originated from the third edition of
`
`Modern Pharmaceutics rather than the fourth edition.
`
`7. Moreover, a POSA would also have known that either edition was
`
`publicly available well prior to the earliest filing date of the ’945 patent. The
`
`publication pages of each of the references show that they were published in 1996
`
`and 2002, respectively, by CRC Press and provide an ISBN number. In addition, a
`
`POSA, seeking to purchase the third edition online would have noted that vendors
`
`selling this text book indicate that the third edition of Modern Pharmaceutics was
`
`published in 1996 (see, e.g., Ex. 1042) and the fourth edition was published in
`
`2002 (see, e.g., Ex. 1043). Therefore, a POSA would have known that Rudnic was
`
`publicly available as of its respective publication dates in the third and fourth
`
`editions.
`
`
`
`
`
`5
`
`
`
`
`
`
`
`
`I declare under penalty of perjury under the law of the United States that all
`
`statements made herein of my own knowledge are true and that all statements
`
`made on information and belief are believed to be true; and further that these
`
`statements were made with the knowledge that willful false statements and the like
`
`so made are punishable by fine or imprisonment, or both, under Section 1001 of
`
`Title 18 of the United States Code.
`
`
`
`
`
`
`
`
`Executed on the 26th day of November, 2018, by:
`
`
`
`
`
`
`
`
`
`
`
`
`
`_________________________________
`
`Dr. Kinam Park, Ph.D.
`
`6
`
`